Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis.
about
Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: A multicenter retrospective cohort study in Japan.The etiology of B-cell lymphoid malignancies with a focus on chronic inflammation and infections.Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics' register GISEA.[Rheumatoid symptoms in patients with hematologic neoplasms].RANKL: A therapeutic target for bone destruction in rheumatoid arthritis.Prediction of successful dose reduction or discontinuation of adalimumab, etanercept, or infliximab in rheumatoid arthritis patients using serum drug levels and antidrug antibody measurement.Comorbidities in Spondyloarthritis.Anti-inflammatory therapy with canakinumab for atherosclerotic disease: lessons from the CANTOS trial.Total Joint Arthroplasty in Patients with Inflammatory Rheumatic DiseasesSinomenine Inhibits the Progression of Rheumatoid Arthritis by Regulating the Secretion of Inflammatory Cytokines and Monocyte/Macrophage SubsetsGender Is a Risk Factor for Annual Decline in Estimated Glomerular Filtration Rate in Patients Treated with Biological DMARDs in Rheumatoid Arthritis and Ankylosing Spondylitis: a Retrospective Observational Study
P2860
Q33778719-9605EB89-4087-41E9-88F2-E462B14B364CQ40056500-35C5CAF5-F814-4EE4-8AC1-62607ABEE0DCQ47861250-2DC5024C-B4BD-4C65-87F3-B2C29B1609C9Q50057578-73892ADB-FB89-47AE-9272-F261EFB0B8FFQ50207113-DA42FFA2-474C-4F8B-BAAE-DC8FA5BDA1EEQ51046105-7AD8B753-3372-4741-B0A9-F5A31E15C0DFQ54246292-32EAF263-587A-43F3-9143-5433C9464714Q55175882-9895768C-FA0E-49E5-8B58-6B3CCB1B84C9Q57176362-1A2925BD-7888-4423-9D73-B14D0A8B9AFEQ57491401-2926F156-3147-4421-B3AD-CCEDF0E2B7C4Q57985170-CCE9A875-A323-4B5A-B2AA-BCEC6DB2F0FB
P2860
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Safety of synthetic and biolog ...... ement of rheumatoid arthritis.
@en
Safety of synthetic and biolog ...... ement of rheumatoid arthritis.
@nl
type
label
Safety of synthetic and biolog ...... ement of rheumatoid arthritis.
@en
Safety of synthetic and biolog ...... ement of rheumatoid arthritis.
@nl
prefLabel
Safety of synthetic and biolog ...... ement of rheumatoid arthritis.
@en
Safety of synthetic and biolog ...... ement of rheumatoid arthritis.
@nl
P2093
P50
P1476
Safety of synthetic and biolog ...... ement of rheumatoid arthritis.
@en
P2093
Jackie L Nam
Johannes W Bijlsma
Katerina Chatzidionysiou
Marieke Scholte-Voshaar
Robert B M Landewé
P304
P356
10.1136/ANNRHEUMDIS-2016-210708
P407
P50
P577
2017-03-15T00:00:00Z